HTML for Moodle

Frailty and Comprehensive Geriatric Assessment

Geriatric and Palliative Medicine
Topics 1–4
Topics to be covered
  1. 1Frailty: pathophysiology of sarcopenia, frailty phenotype, Clinical Frailty Scale
  2. 2Comprehensive geriatric assessment: domains and multimorbidity management
  3. 3Falls in older adults: risk factors, postural hypotension, bone protection
  4. 4Multimorbidity and clinical complexity
Applies across this moduleManaging frailty and multimorbidity draws on medication review and deprescribing, covered in Prescribing in older adults (topics 11-12), and on advance care planning, covered in Ethics, law and advance care planning (topics 17-18). 
Key points
 
Topic 1
 

Frailty: pathophysiology of sarcopenia, frailty phenotype, Clinical Frailty Scale

Learning outcomes – what you need to know
High-yield clinical fact The Clinical Frailty Scale must reflect the patient's premorbid baseline function over the two weeks before any acute illness, not their current state. Assessing on acute presentation systematically overestimates frailty and can lead to inappropriate clinical decisions.
Frailty phenotype (Fried criteria) – WEAKS
W – Weight loss (unintentional, >4.5 kg or >5% in the past year)
E – Exhaustion (self-reported fatigue on CES-D items)
A – Activity (low physical activity, lowest quintile of kcal/week)
K – Kinesis: slow gait speed (sex- and height-adjusted threshold)
S – Strength: weak grip strength (sex- and BMI-adjusted threshold)
Three or more criteria = frailty  ·  one or two = pre-frailty  ·  zero = robust
Pathophysiology of sarcopenia

Sarcopenia, defined by the European Working Group on Sarcopenia in Older People (EWGSOP2, 2019) as a progressive, generalised skeletal muscle disorder associated with adverse outcomes including falls, functional decline, frailty and death, is the central biological substrate of the frailty syndrome. Its aetiology is multifactorial, arising from interplay between neurological, endocrine, immunological and metabolic dysregulation accumulating across the lifecourse.

Cellular and neuromuscular changes

Ageing muscle undergoes progressive denervation of fast-twitch type II motor units that are not adequately reinnervated. The result is reduced muscle fibre cross-sectional area, preferential atrophy of glycolytic fast-twitch fibres and relative preservation of slow-twitch oxidative type I fibres. This shift impairs the capacity to generate rapid, powerful contractions – the physiological basis for slow gait speed and difficulty rising from a chair, both cardinal frailty features.

Anabolic hormonal decline

Testosterone, insulin-like growth factor-1 (IGF-1) and dehydroepiandrosterone (DHEA) all fall progressively from the fifth decade. Reduced IGF-1 signalling through the phosphoinositide 3-kinase (PI3K)–Akt–mTOR pathway diminishes protein synthesis and satellite cell activation, impairing muscle repair and hypertrophy. Growth hormone secretion also declines, reducing hepatic IGF-1 production through the somatotrophic axis.

Inflammaging

A chronic low-grade inflammatory state, termed “inflammaging”, further drives sarcopenic muscle loss. Elevated interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α) and C-reactive protein activate the nuclear factor kappa-B (NF-κB) pathway within myocytes, upregulating the ubiquitin-proteasome degradation system and promoting net protein catabolism. This is perpetuated by adipose-derived cytokines, falling oestrogen (which has anti-inflammatory properties) and impaired mitochondrial function with attendant reactive oxygen species (ROS).

Mitochondrial dysfunction

Ageing mitochondria accumulate somatic mutations in mitochondrial DNA, show reduced oxidative phosphorylation efficiency and produce excess ROS. Impaired mitophagy allows damaged organelles to accumulate. The resulting energy deficit impairs protein synthesis, reduces satellite cell function and promotes apoptosis of myonuclei, accelerating loss of muscle mass and function.

Nutritional factors

Inadequate dietary protein, particularly during catabolic illness, compounds the age-related fall in muscle protein synthesis. The recommended protein intake for older adults at risk of sarcopenia is 1.0–1.2 g/kg/day at minimum (ESPEN), rising to 1.2–1.5 g/kg/day during acute illness. Vitamin D deficiency, highly prevalent in older UK adults, independently impairs muscle function through vitamin D receptor (VDR)-mediated transcription of genes encoding contractile proteins.

The frailty phenotype and its clinical application
Operationalising the phenotype

Fried and colleagues (2001) operationalised frailty as a distinct clinical syndrome defined by five measurable features: unintentional weight loss (>4.5 kg or >5% of body weight in the preceding year), self-reported exhaustion (from Centre for Epidemiological Studies Depression Scale items), weak grip strength (below sex- and BMI-stratified thresholds), slow walking speed (below sex- and height-stratified thresholds over 4.57 metres) and low physical activity (below the lowest quintile of weekly kilocalorie expenditure). Three or more criteria define frailty; one or two define a pre-frailty state associated with significant risk of progression; zero defines robustness.

Predictive validity and biological basis

The phenotype has been validated across multiple prospective cohorts as an independent predictor of hospitalisation, disability, institutionalisation and death, even after adjustment for age, comorbidity and cognitive status. Its criteria map onto discrete biological pathways: weight loss reflects negative energy balance from inflammaging and anorexia of ageing; exhaustion reflects mitochondrial insufficiency and anaemia; weakness and slowness reflect sarcopenia; and low activity both reflects and perpetuates the syndrome in a self-reinforcing cycle.

Clinical applicability

The phenotype model is most applicable in community and outpatient settings, where time allows formal measurement of walking speed and grip strength. In the acute hospital its operationalisation is often impractical, and the Clinical Frailty Scale offers a validated, efficient alternative.

The Clinical Frailty Scale and the cumulative deficit model
The Clinical Frailty Scale

The Clinical Frailty Scale (CFS), developed by Rockwood and colleagues in the Canadian Study of Health and Aging, is a nine-point ordinal scale characterising frailty from clinical judgement about a patient's mobility, energy, physical activity and function in the two weeks before an acute illness. Scores range from 1 (Very Fit) to 9 (Terminally Ill). Scores of 5 (Mildly Frail) to 6 (Moderately Frail) identify people who clearly depend on others for higher-order activities of daily living; scores of 7 (Severely Frail) and above indicate dependence for personal care or complete dependence.

Validation and appropriate use

The CFS is extensively validated in acute settings and endorsed by NHS England, NICE and the British Geriatrics Society. It predicts inpatient mortality, discharge destination, prolonged length of stay and 30-day readmission. Its applicability in critical-care framing was widely debated during the COVID-19 pandemic; it must reflect premorbid status rather than the condition at assessment, and must not be applied to patients with stable disability (for example stable paraplegia or stable cerebral palsy), where scores would misleadingly classify non-progressive impairment as frailty.

The cumulative deficit model

The cumulative deficit model, also developed by Rockwood, conceptualises frailty as the accumulation of deficits across health domains: symptoms, signs, diagnoses, laboratory abnormalities and functional impairments. The Frailty Index is the ratio of deficits present to deficits considered, expressed as a proportion; a Frailty Index above 0.25 indicates frailty. It has superior predictive validity for mortality at population level and can be derived from routinely collected data, making it valuable for research and epidemiology, though less practical at the bedside.

Feature Frailty phenotype (Fried) Cumulative deficit (Frailty Index)
Concept Frailty as a discrete clinical syndrome Frailty as accumulation of health deficits
Measurement Five criteria (WEAKS), formally measured Ratio of deficits present to deficits considered
Threshold 3 or more = frail; 1–2 = pre-frail Frailty Index >0.25 = frail
Best setting Community and outpatient Research and population, from routine data or the electronic health record
Strength Identifies a discrete, physiologically grounded syndrome Superior population-level prediction of mortality

Both models measure frailty but through different conceptual lenses, and they do not always agree at the individual level.

Management of frailty

No pharmacological agent has been shown to reverse frailty. The most robust evidence supports structured, progressive resistance exercise as the cornerstone intervention. Resistance training at moderate-to-high intensity (70–85% of one-repetition maximum), performed two to three times weekly, increases muscle mass, strength and physical performance in frail older adults. The SPRINTT trial (2019) showed that physical activity combined with dietary protein supplementation reduced mobility disability in community-dwelling frail and pre-frail older adults.

Nutritional optimisation is an essential adjunct: dietitian assessment, correction of protein-energy malnutrition, vitamin D supplementation (800 IU daily in those at risk, per NICE PH56) and management of the anorexia of ageing. Oral nutritional supplements may be warranted where dietary modification alone is insufficient, guided by MUST (Malnutrition Universal Screening Tool) scoring. Comprehensive geriatric assessment (CGA), covered in Topic 2, provides the systematic framework within which frailty interventions are delivered, and has the strongest evidence for improving outcomes in frail older adults admitted to hospital.

Guidelines
  • NICE PH56 – vitamin D supplementation
  • NICE NG56 – multimorbidity (relevant to frailty management)
  • British Geriatrics Society Best Practice Guidance on Frailty (2014, updated)
  • EWGSOP2 consensus 2019 – sarcopenia diagnosis
Frameworks
  • Fried frailty phenotype (5-item)
  • Clinical Frailty Scale (Rockwood, 9-point)
  • Frailty Index / cumulative deficit model
  • MUST
Pharmacology
  • No licensed pharmacological intervention for frailty
  • Vitamin D (cholecalciferol; VDR-mediated transcription)
  • Protein supplementation (essential amino acids stimulate mTOR-dependent muscle protein synthesis)
CIP domains
  • Managing long-term conditions and promoting patient health
  • Clinical assessment and managing uncertainty
  • Clinical management
Summary – key takeaways
 
Topic 2
 

Comprehensive geriatric assessment: domains and multimorbidity management

Learning outcomes – what you need to know
High-yield clinical fact Cochrane evidence (Ellis 2017) shows that ward-based CGA, not CGA consultation, significantly increases the probability of a patient being alive and living in their own home at 6–12 months. This is the strongest evidence base for any model of geriatric care delivery and underpins NHS commissioning of dedicated geriatric wards.
Definition and conceptual basis

Comprehensive geriatric assessment is a multidimensional, interdisciplinary diagnostic process that determines the medical, psychological, functional and social capabilities and limitations of an older frail person, with the aim of developing an integrated plan for treatment and long-term follow-up. It is not simply a clinical assessment: it is a coordinated, goal-directed process in which the multidisciplinary team aggregates data across domains to generate an individualised care plan addressing the totality of the patient's needs rather than isolated disease episodes.

Its theoretical basis is the recognition that frailty and multimorbidity produce interdependent problems: functional impairment may worsen cognition, polypharmacy may precipitate delirium, and social isolation may impede recovery from acute illness. A single-organ approach is therefore insufficient; CGA provides the structure for holistic evaluation and for coordinating interventions across multiple domains at once.

Domains of CGA

CGA is organised around seven domains, each with validated assessment tools. In older frail patients the most important clinical issue may not be the presenting complaint, so a complete problem list across all domains is essential.

Domain What it assesses Validated tools
Medical History, examination, diagnoses, investigations, medication burden, complete problem list Structured medication review (Topics 14–15)
Functional Basic ADLs (bathing, dressing, toileting, transferring, continence, feeding) and instrumental ADLs (shopping, cooking, finances, medication, transport) Katz Index, Lawton–Brody Scale, Barthel Index (0–100)
Cognitive Delirium and cognitive impairment screening and profiling AMTS (10 items; <8 warrants further assessment), MoCA (30), ACE-III (100)
Psychological Mood, particularly depression (often underdiagnosed) and anxiety GDS-15, PHQ-9
Social Living situation, informal carer support, networks, finances, housing, carer breakdown risk Carer assessment under the Care Act 2014
Environmental Home safety and accessibility; hazards; access to essential facilities Occupational therapy home assessment
Nutritional Malnutrition risk (associated with longer stay, complications, mortality) MUST, Mini Nutritional Assessment (MNA)
Evidence base for CGA delivery

The landmark Cochrane meta-analysis by Ellis and colleagues (2017, updated), encompassing more than 16 randomised controlled trials, showed that CGA delivered on a dedicated geriatric ward (ward-based CGA) significantly improved rates of living at home at 6–12 months and reduced death or institutionalisation compared with standard acute care. The number needed to treat for one additional patient living at home was approximately 33. Ward-based CGA was consistently superior to CGA consultation models, in which a geriatric team advises on a non-geriatric ward; the consultation model showed no significant benefit in the meta-analysis.

In community settings, CGA delivered through specialised community geriatric services (intermediate care, reablement, community multidisciplinary teams) reduces care home admissions and supports independence. Frailty units, ambulatory care pathways and frailty surgery liaison services extend CGA principles to the peri-operative, emergency and outpatient domains. NICE NG56 (Multimorbidity, 2016) recommends that patients with multimorbidity receive care that is coordinated, individualised and minimises treatment burden.

CGA in multimorbidity

Multimorbidity, the presence of two or more long-term conditions, affects over 50% of those aged over 75 in the UK and is the default state of patients seen by geriatricians. Its complexity arises not only from coexisting conditions but from their interactions, the cumulative burden of treatment and competing priorities between disease-specific guidelines. NICE NG56 cautions against the uncritical application of single-disease guidelines in multimorbidity, where adherence to each guideline simultaneously may cause inappropriate polypharmacy, quality-of-life impairment and unsafe drug combinations.

Within CGA, multimorbidity is managed through an iterative process of problem prioritisation, shared decision-making about treatment goals (the relative importance of life extension, symptom control and maintenance of function), medication review (Topics 14–15) and advance care planning (Topics 20–21). Goal concordance, ensuring the plan reflects the patient's own priorities, is both ethically required under the Mental Capacity Act 2005 and clinically associated with improved adherence and outcomes.

Guidelines
  • NICE NG56 – multimorbidity (2016)
  • NICE NG97 – dementia assessment and management
  • Cochrane review, Ellis et al. 2017 (CGA)
  • Care Act 2014 – carer assessment duties
  • British Geriatrics Society CGA toolkit
Frameworks
  • Barthel Index (BADL quantification)
  • Katz Index; Lawton–Brody Scale (IADL)
  • MoCA; ACE-III; AMTS (cognition)
  • GDS-15 (geriatric depression)
  • MUST (malnutrition screening)
Pharmacology
  • No specific pharmacology for CGA; medication review integral (Topics 14–15)
  • Oral nutritional supplements (protein-energy enriched)
  • Vitamin D (cholecalciferol 800 IU/day)
CIP domains
  • Managing long-term conditions
  • Clinical assessment and managing uncertainty
  • Working with patients and families
  • Multidisciplinary and interprofessional working
Summary – key takeaways
 
Topic 3
 

Falls in older adults: risk factors, postural hypotension, bone protection

Learning outcomes – what you need to know
High-yield clinical fact A fragility fracture – any fracture from minimal trauma equivalent to a fall from standing height or less – is a clinical diagnosis of osteoporosis regardless of the DXA T-score. In patients aged over 75 presenting with a fragility fracture, bone protection should be started without waiting for DXA confirmation (NOGG 2021).
Falls risk factors – DAME PIVOTS
D – Drugs (psychotropics, antihypertensives, opioids, alpha-blockers)
A – Age-related changes (baroreceptor sensitivity, muscle mass, vision)
M – Musculoskeletal (sarcopenia, arthritis, foot problems)
E – Environment (rugs, lighting, stairs, ill-fitting footwear)
P – Postural hypotension
I – Impaired cognition or vision
V – Vestibular dysfunction or vertigo
O – Other medical (Parkinson's, stroke, neuropathy, hypoglycaemia)
T – Training deficiency (deconditioning, lack of balance exercise)
S – Syncope or near-syncope
Epidemiology and risk factors
Epidemiology

About one-third of community-dwelling adults over 65, and half of those over 80, fall each year. Falls are the leading cause of injury-related hospitalisation and death in older adults in the UK, with hip fracture the most devastating consequence. Beyond injury, falls produce a cycle of fear, reduced activity, deconditioning and further falls – the post-fall syndrome. The direct cost to the NHS exceeds £2 billion annually.

Intrinsic risk factors

These include impaired balance and gait (vestibular dysfunction, cerebellar disease, peripheral neuropathy), lower-limb muscle weakness (sarcopenia), visual impairment (reduced acuity, contrast sensitivity and depth perception), cognitive impairment (particularly executive dysfunction impairing hazard avoidance) and postural hypotension. Contributing comorbidities include Parkinson's disease (rigidity, festinating gait, impaired postural reflexes), stroke, vitamin D deficiency and uncontrolled diabetes causing hypoglycaemia or peripheral neuropathy.

Polypharmacy

Polypharmacy is a critical modifiable risk factor. Fall-associated medications include psychotropics (benzodiazepines, antipsychotics, antidepressants, which impair reaction time and balance), antihypertensives (postural hypotension), opioids and hypoglycaemic agents. The STOPP (Screening Tool of Older Persons' Prescriptions) criteria identify medications inappropriately prescribed in older adults at risk of falls, and NICE NG249 (2025) makes medication review a mandatory component of any falls assessment.

Extrinsic risk factors

Environmental hazards interact with intrinsic vulnerability to precipitate a fall: loose floor coverings, poor lighting, absence of grab rails in bathrooms and on stairs, ill-fitting footwear and external hazards such as uneven pavements. Occupational therapy home assessment is an evidence-based intervention for identifying and remediating these hazards, with the strongest evidence in people with a history of falls.

Postural (orthostatic) hypotension
Definition and prevalence

Postural hypotension is a sustained fall in systolic blood pressure of at least 20 mmHg, or diastolic of at least 10 mmHg, within three minutes of standing from supine or seated. It affects around 20% of community-dwelling older adults and up to 50% of nursing home residents, and is an independent risk factor for falls, syncope and cardiovascular events.

Physiology

On standing, gravitational pooling of 500–1000 mL of blood in the splanchnic and lower-limb venous system reduces cardiac preload and blood pressure. In healthy individuals, carotid sinus and aortic arch baroreceptors trigger reflex tachycardia and peripheral vasoconstriction to restore pressure within 30 seconds. In older adults this reflex is attenuated by reduced baroreceptor sensitivity and impaired autonomic function.

Causes

Causes are neurogenic (autonomic failure, idiopathic, Parkinson's disease, multiple system atrophy, diabetes) and non-neurogenic (volume depletion from dehydration, blood loss or diuretics; cardiac pump failure; vasodilatory medications including ACE inhibitors, alpha-blockers and nitrates). Iatrogenic causes are the most common and important modifiable factor, with antihypertensives, diuretics, tricyclic antidepressants, alpha-blockers (for benign prostatic hypertrophy) and antiparkinsonian agents all implicated.

Assessment

Assessment requires lying and standing blood pressure, ideally with one- and three-minute readings (the Active Stand test). Investigations include electrolytes and renal function (volume status), full blood count (anaemia), lying and standing heart rate (neurogenic postural hypotension typically shows an inadequate heart rate rise), ECG, and echocardiography where a cardiac cause is suspected.

Management

Management includes medication review and reduction, adequate hydration, compression hosiery, head-of-bed elevation, small frequent meals (to reduce post-prandial hypotension) and physical countermanoeuvres. Where non-pharmacological measures are insufficient, fludrocortisone (a mineralocorticoid) or midodrine (an alpha-1 adrenoceptor agonist) may be considered.

Multifactorial falls assessment

NICE NG249 (2025) recommends that older adults presenting after a fall, or identified as at risk, are asked about falls in the past 12 months and offered a multifactorial assessment where indicated, covering gait, balance and mobility (for example the Timed Up and Go test and the Berg Balance Scale). The Timed Up and Go test measures the time to rise from a chair, walk 3 metres, turn, walk back and sit. NICE NG249 recommends against using timed test cut-offs or falls risk-prediction tools to predict future falls; the Timed Up and Go informs functional assessment and intervention planning rather than risk stratification.

Interventions proven to reduce falls and fall-related injuries include supervised strength and balance exercise programmes (OTAGO, FaME – Falls Management Exercise), home hazard modification, gradual withdrawal of psychotropic medication, antihypertensive dose reduction where clinically appropriate, vitamin D supplementation (800 IU/day in those at risk, per NICE PH56) and, for those at fracture risk, bone protection therapy. Multifactorial interventions are more effective than single-component interventions (Cochrane 2019, Sherrington et al.).

Fracture risk assessment and bone protection

Falls assessment must integrate fracture risk assessment. The FRAX tool (WHO), using clinical risk factors and optionally femoral neck bone mineral density from DXA, calculates the 10-year probability of a major osteoporotic fracture (hip, spine, wrist, humerus) and of hip fracture specifically. In the UK, FRAX is interpreted against the NOGG (National Osteoporosis Guideline Group) thresholds, which stratify patients into treatment, assessment (DXA required before decision) and reassurance categories.

DXA measures bone mineral density at the lumbar spine and femoral neck, expressed as a T-score (standard deviations from mean young adult density) and Z-score (standard deviations from an age-matched mean). A fragility fracture – a fracture from a force equivalent to a fall from standing height or less – is a clinical diagnosis of osteoporosis regardless of T-score and should trigger bone protection therapy.

Category T-score (WHO) Note
Normal -1.0 or above Measured at lumbar spine or femoral neck
Osteopenia -1.0 to -2.5 Reduced density, below the osteoporosis threshold
Osteoporosis -2.5 or below Also diagnosed clinically by any fragility fracture, whatever the T-score

First-line pharmacological bone protection in postmenopausal women and men over 50 with osteoporosis or a fragility fracture is an oral bisphosphonate: alendronic acid 70 mg weekly (NICE TA464). Calcium and vitamin D (calcium carbonate 1200 mg daily, vitamin D 800 IU daily) should be co-prescribed unless dietary intake is sufficient.

Drug Class and mechanism Route, line and notes
Alendronic acid 70 mg weekly Nitrogen-containing bisphosphonate; inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, impairing osteoclast function Oral, first-line (NICE TA464). Reduces vertebral fracture risk ~45% and hip fracture ~51% (FIT trial)
Zoledronic acid 5 mg Bisphosphonate (as above) IV annually; for oesophageal dysmotility or inability to remain upright (NICE TA464)
Denosumab 60 mg Monoclonal antibody targeting RANK-L; inhibits osteoclast differentiation and function Subcutaneous every 6 months (NICE TA204). Do not stop without transitioning to a bisphosphonate (rebound fracture risk)
Romosozumab Sclerostin inhibitor; dual anabolic and anti-resorptive action For severe osteoporosis or bisphosphonate failure (NICE guidance)
Teriparatide Recombinant parathyroid hormone 1-34; anabolic, stimulates osteoblasts For severe osteoporosis with multiple fractures or bisphosphonate failure
Caution Denosumab must not be discontinued without transitioning to a bisphosphonate: stopping it abruptly is associated with rebound vertebral fractures.
Guidelines
  • NICE NG249 – falls: assessment and prevention (2025)
  • NICE TA464 – bisphosphonates for osteoporosis
  • NICE TA204 – denosumab
  • NOGG 2021 – prevention and treatment of osteoporosis
  • NICE PH56 – vitamin D
Frameworks
  • FRAX (WHO 10-year fracture risk)
  • NOGG intervention thresholds
  • Timed Up and Go; Berg Balance Scale
  • Active Stand test (postural hypotension)
  • STOPP/START criteria; MUST
Pharmacology
  • Bisphosphonates (alendronate, zoledronic acid) – inhibit farnesyl pyrophosphate synthase
  • Denosumab – anti-RANKL monoclonal antibody
  • Teriparatide – recombinant PTH 1-34, anabolic
  • Romosozumab – sclerostin inhibitor
  • Fludrocortisone (mineralocorticoid); midodrine (alpha-1 agonist)
CIP domains
  • Managing long-term conditions
  • Clinical assessment and managing uncertainty
  • Clinical management
  • Prescribing safely
Summary – key takeaways
 
Topic 4
 

Multimorbidity and clinical complexity

Learning outcomes – what you need to know
High-yield clinical fact NICE NG56 explicitly advises clinicians not to apply single-disease guidelines uncritically in multimorbidity. The cumulative harm from polypharmacy and treatment burden often outweighs the marginal benefit of achieving guideline-defined targets for each individual condition.
Definitions and epidemiology

Multimorbidity is the presence of two or more long-term physical or mental health conditions in one individual simultaneously. It is distinct from comorbidity, which implies a primary index condition with additional conditions viewed as secondary. Multimorbidity is the norm rather than the exception in older adults: by age 65, more than half the UK population has at least two long-term conditions, rising to over 70% by age 75. Prevalence is disproportionately high in areas of socioeconomic deprivation, occurring on average 10–15 years earlier in deprived populations.

Sources of clinical complexity

Clinical complexity in multimorbidity arises from several interrelated sources:

  • Pathophysiological interactions create non-linear presentations: heart failure and COPD may each exacerbate the other; renal impairment modifies both drug choice and disease progression in diabetes and hypertension.
  • Treatment of one condition may harm another: NSAIDs for osteoarthritis worsen renal function and precipitate heart failure; corticosteroids accelerate osteoporosis and worsen glycaemic control; antihypertensives may precipitate postural hypotension and falls.
  • Single-disease guidelines, developed through trials that systematically excluded patients with multimorbidity, generate conflicting recommendations when applied simultaneously.
Treatment burden

Treatment burden is the total workload imposed on a patient by their healthcare: medication administration and monitoring, attendance at multiple appointments across specialties, lifestyle modifications, dietary restrictions and self-monitoring tasks such as blood glucose or blood pressure recording. In multimorbidity this burden can become overwhelming, leading to reduced adherence, reduced engagement with services and paradoxical worsening of outcomes. Patients with high treatment burden describe healthcare as a second job. Tran and colleagues (2012) conceptualised treatment burden as a construct distinct from disease burden, influenced by healthcare system organisation, patient health literacy and social support.

NICE NG56 principles for multimorbidity

NICE NG56 (2016) sets out specific guidance for managing patients with multiple long-term conditions. Key principles include: taking a patient-centred approach to identify priorities, preferences and concerns; discussing the benefits and harms of individual treatments in the context of all conditions; considering reducing or stopping medications that cause harm or offer limited benefit in the context of multimorbidity; and ensuring care is coordinated across primary and secondary care. NICE NG56 explicitly recommends against applying single-condition guidelines without considering their combined impact.

Shared decision-making is central. Using validated tools such as the Option Grid or structured consultation frameworks, clinicians should explore treatment preferences, priorities among competing outcomes (for example prioritising symptom management over mortality reduction) and tolerance for treatment burden. This process is ethically grounded in autonomy and beneficence and is pragmatically associated with improved adherence, as patients who contribute to decisions are more likely to sustain agreed interventions.

Guidelines
  • NICE NG56 – multimorbidity (2016)
  • NICE NG5 – medicines optimisation
  • Care Act 2014
Frameworks
  • Option Grid (patient decision aids)
  • Minimally Disruptive Medicine (May et al.)
  • Treatment burden assessment
  • Shared decision-making
Pharmacology
  • NSAIDs – nephrotoxicity, fluid retention in heart failure
  • Corticosteroids – hyperglycaemia, osteoporosis
  • ACE inhibitors – hyperkalaemia in CKD
  • Beta-blockers – masking hypoglycaemia, worsening COPD
CIP domains
  • Managing long-term conditions
  • Working with patients and their families
  • Prescribing safely
  • Clinical management
Summary – key takeaways